This study aims to examine the effects of a lifestyle intervention based on a health belief model (HBM) supported by mobile health (mHealth) and the impact of continuous glucose monitoring (CGM) on maternal glycemic parameters, cardiometabolic risk, health behavior and infant's outcomes among women diagnosed with gestational diabetes mellitus (GDM).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with Abnormal Maternal Oral Glucose Tolerance Test Results
Timeframe: 24-32 weeks of pregnancy, 4-12 weeks postpartum
HOMA-IR Value for Assessing Insulin Resistance in Participants
Timeframe: 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery and 4-12 weeks postpartum
Total Cholesterol Levels in Participants
Timeframe: 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery and 4-12 weeks postpartum
Triglycerides Levels in Participants
Timeframe: 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery and 4-12 weeks postpartum
High-density Lipoprotein Levels in Participants
Timeframe: 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery and 4-12 weeks postpartum
Low-density Lipoprotein Levels in Participants
Timeframe: 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery and 4-12 weeks postpartum
Glycated Albumin Levels in Participants
Timeframe: 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery and 4-12 weeks postpartum
Fasting Plasma Glucose Levels in Participants
Timeframe: 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery and 4-12 weeks postpartum
Incidence of Fetal Macrosomia as Measured by Birth Weight
Timeframe: 4-12 weeks postpartum